Frontiers | Notch2 Increases the Resistance to Venetoclax-In

Chronic lymphocytic leukemia (CLL) has experienced a clinical revolution thanks to the discovery of crucial pathogenetic mechanisms. CLL is still an incurable disease due to intrinsic or acquired resistance of the leukemic clone. Venetoclax is a Bcl-2 inhibitor with a marked activity in CLL, but emerging patterns of resistance are being described. We hypothesize that intrinsic features of CLL cells may contribute to drive mechanisms of resistance to venetoclax. We analyzed the expression of IRF4, Notch2 and Mcl-1 in a cohort of CLL patients. We evaluated CLL cells viability after genetic and pharmaceutical modulation of Notch2 expression in patients harboring trisomy 12. We tested venetoclax in trisomy 12 CLL cells either silenced or not for Notch2 expression or in combination with an inhibitor of Mcl-1, AMG-176. Trisomy 12 CLL cells were characterized by low expression of IRF4 associated with high levels of Notch2 and Mcl-1. Notch2 and Mcl-1 expression determined protection of CLL cells from spontaneous and drug-induced apoptosis. Considering the involvement of Mcl-1 in venetoclax resistance, our data demonstrated a contribution of high levels of Notch2 and Mcl-1 in a reduced response to venetoclax in CLL cells carrying trisomy 12. Furthermore, reduction of Mcl-1 expression by silencing Notch2 or by treatment with AMG-176 were able to restore the response of CLL cells to venetoclax. The expression of Notch2 identifies a subset of CLL patients, mainly harboring trisomy 12, characterized by high levels of Mcl-1. This biological mechanism may compromise an effective response to venetoclax.

Related Keywords

United States , Helsinki , Eteläuomen Läi , Finland , Milan , Lombardia , Italy , Rockville , California , Menlo Park , Valencia , Carabobo , Venezuela , Uppsala , Uppsala Lan , Sweden , Milpitas , Caldana , Toscana , Isasi , Landskapet Birkaland , Tissino , Italy General , San Diego , Carette , Fondazione Cariplo , Ricerca Sul Cancro , Associazione Italiana , Progetto Eccellenza , Stefania Benatti , Fondazione Umberto Veronesi , Nucleofector Lonza , Comitato Etico Provinciale , Gilead Sciences , Becton Dickinson , Associates With Nodal Presentation , Pfizer , Image Lab Software , Flowjo Software , Division Of Hematology Modena , Deletion Accelerates Chronic Lymphocytic Leukemia Development , Late Germinal Center Differentiation , Subsequent Development Of Lymphadenopathy , Ge Healthcare , Tumor Protein , B Cell Receptor , Lymphocytic Leukemia Patients , Miltenyi Biotech , Master Mix , Life Technologies , Light Cycler , Applied Biosystems , Origene Technologies , Annexinv Fluorescein , San Jos , Bio Rad Laboratories , Westernbright Sirius , Graphpad Prism , Supplementary Material , Patrizia Zucchini , Chronic Lymphocytic , Med Abstract , Crossref Full Text , With Trisomy , Main Genetic Pathways Lead , Chronic Lymphocytic Leukemia , Relapsed Chronic Lymphocytic , Finka M , Patients With , Refractory Chronic Lymphocytic Leukaemia With , Lancet Oncol , Predictive Impact , Genetic Markers , With Obinutuzumab , Acquired Resistance , B Cell Lymphoproliferative , Leuk Lymphoma , Novel Venetoclax Resistance Mutation , Agonists Generatede Novophenotypic Resistance , Combined Ibrutinib Plus Venetoclax , Lymphocytic Leukemia Patients Is Mediated , Diverse Roles , Late Germinal Centerb Cell , Immunol Rev , Cell Specific , Enhanced Tumor Immune , Chronic Lymphocytic Leukemia Regulating , Regulatory Factor , Notch Signaling , Microenvironmental Signals , Chronic Lymphocytic Leukemia Can , Shows Preclinical Efficacy , Clin Cancer Res , Efficiently Induces Apoptosis , Chronic Lymphocytic Leukaemia , Matureb Cells , Lymphoid Microenvironments , Activated Notch Signaling Is Involved , Apoptosis Resistance , Proteasome Inhibitors , B Cell Chronic Lymphocytic , L Dependent Resistance , Cell Death Dis , B Cell Malignancies , Overcoming Therapeutic , Prolongs Survival , Post Treatment Follow Up , Proc Natl Acad Sci United States , Bidirectional Linkage Between , Genetic Subgroup , Signaling Sustains , Promote Cell Survival , Lymphocytic Leukemia Cells , Methylation Dependent Regulation , Subsequent Development , Hematologic Cancer Models Alone , Combination With Established , Cancer Discov , Inhibitors Differ , Their Ability , Mediated Resistance , Plus Rituximab , Relapsed Chronic Lymphocytic Leukemia , Year Results , Genomic Complexity , Gene Mutations From , Microenvironment In Vivo Activate , Antiapoptotic Multidrug Resistant Phenotype , Chronic Lymphocytic Leukemia Cll , Drug Resistance , Translational Research , Notch , Enetoclax Abt 199 ,